

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MULLEN JAMES C (Last) (First) (Middle) 14 CAMBRIDGE CENTER (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CEO & President
	3. Date of Earliest Transaction (Month/Day/Year) 06/08/2010	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/08/2010		F		8,253	D	\$46.85	122,896	D	
Common Stock	06/08/2010		F		13,628	D	\$46.85	109,268	D	
Common Stock	06/08/2010		F		13,765	D	\$46.85	95,503	D	
Common Stock								75,000	I	2008 GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-qualified Stock Option (Right to Buy)	\$49.03	06/08/2010		D ⁽¹⁾			249,500	(3)	12/14/2011	Common Stock	249,500	(1)	0	D	
Non-qualified Stock Option (Right to Buy)	\$49.03	06/08/2010		A ⁽¹⁾		249,500		(3)	12/14/2011	Common Stock	249,500	(1)	249,500	D	
Stock Option (Right to Buy) ⁽²⁾	\$67.57	06/08/2010		D ⁽¹⁾		325,000		(4)	02/17/2015	Common Stock	325,000	(1)	0	D	
Stock Option (Right to Buy) ⁽²⁾	\$67.57	06/08/2010		A ⁽¹⁾		325,000		(4)	02/17/2015	Common Stock	325,000	(1)	325,000	D	
Stock Option (Right to Buy) ⁽²⁾	\$44.59	06/08/2010		D ⁽¹⁾		120,000		(5)	02/06/2016	Common Stock	120,000	(1)	0	D	
Stock Option (Right to Buy) ⁽²⁾	\$44.59	06/08/2010		A ⁽¹⁾		120,000		(5)	02/06/2016	Common Stock	120,000	(1)	120,000	D	
Stock Option (Right to Buy) ⁽⁶⁾	\$49.17	06/08/2010		D ⁽¹⁾		210,000		(7)	02/12/2017	Common Stock	210,000	(1)	0	D	
Stock Option (Right to Buy) ⁽⁶⁾	\$49.17	06/08/2010		A ⁽¹⁾		210,000		(7)	02/12/2017	Common Stock	210,000	(1)	210,000	D	
Stock Option (Right to Buy)	\$63.24	06/08/2010		D ⁽¹⁾		166,100		(8)	02/12/2018	Common Stock	166,100	(1)	0	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$63.24	06/08/2010		A ⁽¹⁾		166,100		(8)	02/12/2018	Common Stock	166,100	(1)	166,100	D	
Stock Option (Right to Buy)	\$50.55	06/08/2010		D ⁽¹⁾			131,530	(9)	02/25/2019	Common Stock	131,530	(1)	0	D	
Stock Option (Right to Buy)	\$50.55	06/08/2010		A ⁽¹⁾		131,530		(9)	02/25/2019	Common Stock	131,530	(1)	131,530	D	

Explanation of Responses:

- The reported transactions represent amendments to the respective outstanding options (resulting in the deemed cancellation of the "old" option and the grant of a replacement option) extending their post-retirement exercise periods until June 8, 2013 or their expiration, whichever is earlier, pursuant to the Transition Agreement between Biogen Idec Inc. and James C. Mullen dated January 4, 2010. In addition, unvested outstanding options become fully exercisable upon retirement pursuant to the Transaction Agreement.
- Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).
- The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/14/01.
- The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/17/05.
- The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/07/06.
- Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).
- The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/13/2007.
- The stock options become exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/13/2008.
- The stock options become exercisable in four (4) equal annual installments commencing one year after the grant date of 02/25/09.

/s/ Aras Lapinskas, Attorney in 06/10/2010
Fact for James C. Mullen

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.